Whole-Cell Vaccines

Reference work entry

Abstract

Therapeutic cancer vaccines aim to generate tumor immunity through coordinated cell- and antibody-mediated responses that ultimately result in highly specific and potent T cells capable of destroying cancers. Cancer vaccines have unique advantages compared to most other cancer therapeutics, with a high degree of specificity for tumor cells relative to normal tissues, a highly favorable side-effect profile, and the potential for a long-lasting treatment effect due to immunologic memory.

Keywords

Whole-cell vaccine Immunotherapy Immune response Chemotherapy Monoclonal antibody Combination immunotherapy 

References

  1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296–306.CrossRefPubMedGoogle Scholar
  2. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.CrossRefPubMedPubMedCentralGoogle Scholar
  3. De Gruijl TD, et al. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57:1569–77.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Dranoff G, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539–43.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Emens LA. GM-CSF-secreting vaccines for solid tumors. Curr Opin Invest Drugs. 2009;10:1315–24.Google Scholar
  6. Emens LA. Chemoimmunotherapy. Cancer J. 2010;16:295–303.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biol Ther. 2003;2(4)Suppl 1:S161–8.Google Scholar
  8. Emens et al. Cancer vaccines in combination with multimodality therapy. Cancer Treat Res. 2005;123:227–45.Google Scholar
  9. Emens LA, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27:5911–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Emens LA, et al. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012;10:70.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Ferris RL, et al. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28:4390–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med. 2010;10:52–60.PubMedPubMedCentralGoogle Scholar
  13. Higano CS, et al. Integrated data from 2 randomized, double-blind, placebo-controlled phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;155:3670–9.CrossRefGoogle Scholar
  14. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.CrossRefPubMedGoogle Scholar
  16. Laheru DA, et al. Allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455–63.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Le DT, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36:382–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Lutz ER, et al. A lethally-irradiated allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328–35.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227–38.CrossRefPubMedGoogle Scholar
  20. Robert C, et al. Ipilimumab plus dacarbazine for previously treated metastatic melanoma. N Engl J Med. 2011;364:2517–26.CrossRefPubMedGoogle Scholar
  21. Santegoets SJ, et al. T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother. 2013;62:245–55.CrossRefPubMedGoogle Scholar
  22. Schadendorf D, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563–70.CrossRefPubMedGoogle Scholar
  23. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Van den Eertwegh AJ, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase I dose-escalation trial. Lancet Oncol. 2012;13:509–17.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of OncologySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Oncology and the Program in PathobiologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations